Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes supportive care products. The Company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The Company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes, and other product candidates, including other dronabinol line extensions and sublingual spray product candidates.

TypePublic
HQChandler, US
Founded1998
Size (employees)423 (est)
Websiteinsysrx.com
Insys Therapeutics was founded in 1998 and is headquartered in Chandler, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Insys Therapeutics

Saeed Motahari

Saeed Motahari

President and CEO
Andrew Long

Andrew Long

CFO
Franc Del Fosse

Franc Del Fosse

General Counsel
Sanga Emmanuel

Sanga Emmanuel

VP, Chief Compliance Officer
Venkat Goskonda

Venkat Goskonda

Senior VP, Research & Development
Daniel Pon

Daniel Pon

VP, Human Resources
Show more

Insys Therapeutics Office Locations

Insys Therapeutics has offices in Round Rock and Chandler
Chandler, US (HQ)
1333 S Spectrum Blvd #100
Chandler, US
444 S Ellis St and 410 S Benson Ln
Round Rock, US
2700 Oakmont Drive
Show all (3)
Report incorrect company information

Insys Therapeutics Financials and Metrics

Insys Therapeutics Revenue

Insys Therapeutics's revenue was reported to be $140.69 m in FY, 2017
USD

Revenue (Q2, 2018)

47.4m

Gross profit (Q2, 2018)

41.6m

Gross profit margin (Q2, 2018), %

87.8%

Net income (Q2, 2018)

(47.7m)

EBIT (Q2, 2018)

(47.9m)

Market capitalization (18-Oct-2018)

676.4m

Closing stock price (18-Oct-2018)

9.1

Cash (30-Jun-2018)

16.1m
Insys Therapeutics's current market capitalization is $676.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

99.3m222.1m330.8m242.3m140.7m

Revenue growth, %

124%49%(27%)

Cost of goods sold

12.7m28.9m25.4m20.6m

Gross profit

86.6m301.9m216.9m120.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

29.2m41.6m55.7m58.3m70.8m77.6m91.3m62.0m67.1m55.2m36.0m42.6m30.7m23.9m47.4m

Cost of goods sold

3.1m4.8m6.6m5.4m6.4m8.3m7.7m4.6m6.3m4.7m4.6m3.9m7.5m2.2m5.8m

Gross profit

26.1m36.9m49.1m52.9m64.4m69.3m83.6m57.3m60.8m50.5m31.3m38.7m23.2m21.7m41.6m

Gross profit Margin, %

89%89%88%91%91%89%92%93%91%92%87%91%76%91%88%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

45.4m58.1m79.5m104.6m32.0m

Accounts Receivable

Inventories

14.5m34.8m41.7m21.7m17.4m

Current Assets

82.2m151.0m253.2m231.0m175.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

31.3m40.0m46.1m47.4m70.1m74.0m94.0m73.8m69.3m93.5m68.4m49.8m35.8m18.5m16.1m

Accounts Receivable

12.4m19.1m

Inventories

11.7m19.4m24.7m31.4m35.2m35.6m39.4m32.2m29.2m28.0m21.3m20.0m18.4m16.3m10.0m

Current Assets

57.7m91.3m102.2m128.7m182.1m198.2m236.6m220.8m234.0m235.2m196.9m197.2m179.9m166.7m156.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

40.4m58.5m7.6m(228.0m)

Depreciation and Amortization

1.8m2.5m5.3m6.2m7.3m

Inventories

(7.4m)(20.0m)(6.9m)15.0m2.3m

Accounts Payable

Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

7.7m9.5m11.5m8.0m7.3m26.1m2.4m4.4m190.0k(6.5m)(20.4m)(47.7m)

Depreciation and Amortization

1.9m3.8m

Inventories

24.7m31.4m35.2m35.6m39.4m32.2m29.2m28.0m1.0m930.0k

Accounts Payable

15.1m24.5m36.6m30.6m24.2m25.7m22.2m17.5m28.2m
USDY, 2018

Financial Leverage

9.5 x
Show all financial metrics
Report incorrect company information

Insys Therapeutics News and Updates

Johnson Fistel Announces Investigations of Veevo Instruments Inc., Insys Therapeutics, Inc., TAL Education Group and Newell Brands Inc.; Investors Encouraged to Contact Firm

SAN DIEGO, June 23, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Veevo Instruments Inc., Insys Therapeutics, Inc., TAL Education Group and Newell Brands Inc., as detailed below: Veevo Instruments Inc.(VECO) Johnson...
Report incorrect company information

Insys Therapeutics Blogs

Elizabeth Bohlen

Elizabeth Bohlen ma.celeste.loy… Wed, 10/03/2018 - 13:45 Member of the Compliance Committee Member of the Nominating and Corporate Governance Committee Elizabeth Bohlen Directors

INSYS Therapeutics Signs Definitive License Agreement with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East

PHOENIX , Oct. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that it has signed a definitive license agreement with Lunatus for

Insys Therapeutics Company Life and Culture

Report incorrect company information